Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial - PACE-CME

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program credits
- Julia Brandts, MD
0.75 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Prof. Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 program credits
- John Kastelein, MD, PhD
0.50 program credits
Understanding the role of triglycerides in the assessment of residual risk
Understanding the role of triglycerides in the assessment of residual risk
MinuteCE®
Understanding the role of triglycerides in the assessment of residual risk
0.50 program credits
- Prof. Alberto Zambon MD, PhD, FAHA
0.50 program credits